News Snapshot:
Taipei, Sept. 30 (CNA) A COVID-19 vaccine candidate jointly developed by Taiwan's Medigen Vaccine Biologics Corp. and the U.S. National Institutes of Health (NIH) has been authorized to begin human trials, Taiwan's Food and Drug Administration (FDA) said Wednesday. This makes it the third vaccine in the country to receive approval. The MVC-COV1901 vaccine injection received conditional approval for clinical testing on Aug. 31 and was given full approval on Wednesday after Medigen submitted technical documents for additional review, the FDA said. The first stage of the trial, to test for safety, is expected to take place at National Taiwan...
